文献速递慢性肾脏病遗传性与小管间质肾病

骨骼肌质量与体重指数与常染色体显性多囊肾病临床结局的关联:一项观察性研究

Associations of Skeletal Muscle Mass and Body Mass Index With Clinical Outcomes in Autosomal-Dominant Polycystic Kidney Disease: An Observational Study.
PubMed 文献 · Am J Kidney Dis · 2025-10-14

该回顾性队列纳入韩国8家三级医院2006-2020年1443例ADPKD患者,用AI基于第三腰椎CT测骨骼肌面积并区分低衰减与正常衰减肌面积。中位随访5.14年发现骨骼肌面积/身高²及正常衰减肌面积/身高²较高与全因死亡风险降低相关,正常衰减肌面积较高与ESKD风险降低相关,而低衰减肌面积较高与ESKD风险升高相关。

要点

  • ADPKD患者骨骼肌面积/身高²较高与全因死亡风险降低相关(HR 0.58)。
  • 正常衰减肌面积/身高²较高与ESKD风险降低26%相关(HR 0.74)。
  • 低衰减肌面积/身高²较高与ESKD风险升高相关(HR 1.18)。

核心结论

  • 在ADPKD患者中,骨骼肌质量较大且质量较高与较低的死亡风险和CKD进展至ESKD风险相关。

研究设计与样本

  • 回顾性队列研究,纳入韩国8家三级医院2006-2020年1443例ADPKD患者。

主要发现

  • 骨骼肌面积/身高²较高与全因死亡风险降低相关(HR 0.58,95%CI 0.39-0.88)。
  • 正常衰减肌面积/身高²较高与全因死亡风险降低相关(HR 0.55,95%CI 0.39-0.79)。
  • 正常衰减肌面积/身高²较高与ESKD风险降低26%相关(HR 0.74,95%CI 0.59-0.92)。
  • 低衰减肌面积/身高²较高与ESKD风险升高相关(HR 1.18,95%CI 1.01-1.37)。
  • 正常衰减/低衰减肌面积比值较高与ESKD风险降低相关(HR 0.74,95%CI 0.60-0.92)。

临床怎么用

  • 对ADPKD患者可关注骨骼肌质量,尤其肌肉衰减质量,作为死亡和ESKD风险分层的参考。

局限性

  • 缺乏肌肉力量和身体功能的详细信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Low muscle mass is a risk factor for chronic kidney disease. In this study, we examined the relationship between muscle mass and mortality, as well as end-stage kidney disease (ESKD), in patients with autosomal-dominant polycystic kidney disease (ADPKD). STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: 1,443 patients with ADPKD from eight tertiary-care hospitals in South Korea between 2006 and 2020. EXPOSURES: Computed tomography images were obtained at the third lumbar vertebra to measure the skeletal muscle area (SMA) using an artificial intelligence system. SMA indexed for the square of height (height2) was classified as low-attenuation muscle area (LAMA) or normal-attenuation muscle area (NAMA) based on muscle quality. OUTCOMES: All-cause mortality and ESKD. ANALYTICAL APPROACH: Cox proportional hazards regression, adjusted for sex, age, creatinine, glucose, and height-adjusted total kidney volume, was used to investigate the associations of muscle indices with all-cause mortality and ESKD. Subgroup analyses were conducted based on body mass index categories: low or normal (<25 kg/m2) and overweight or obese (≥25 kg/m2). RESULTS: The study population included more than half female patients, and the mean estimated glomerular filtration rate was 68.4 mL/min/1.73 m2. Mean follow-up was 5.14 years. Greater SMA/height2 and NAMA/height2 ratios were associated with a lower risk of mortality (HRs, 0.58 [95% CI, 0.39-0.88] and 0.55 [0.39-0.79], respectively). Greater NAMA/height2 ratio was associated with a 26% lower ESKD incidence (HR, 0.74; 95% CI, 0.59-0.92), but a greater LAMA/height2 ratio was associated with a higher ESKD incidence (HR 1.18, 95% CI 1.01-1.37). A higher NAMA/LAMA ratio was associated with a lower ESKD incidence (HR, 0.74; 95% CI, 0.60-0.92). Greater muscle mass was associated with a lower risk of mortality among overweight individuals and a lower risk of ESKD in underweight individuals. LIMITATIONS: Lack of details about muscle strength and performance. CONCLUSIONS: Among individuals with ADPKD, greater and higher-quality muscle mass were associated with lower risks of mortality and progression of chronic kidney disease to ESKD. PLAIN-LANGUAGE SUMMARY: Low muscle mass is a known health concern, and we aimed to study its impact specifically in patients with autosomal-dominant polycystic kidney disease (ADPKD). We investigated how muscle mass relates to patient survival and progression to end-stage kidney disease. Using computed tomography scans performed on more than 1,400 patients with ADPKD, we measured the amount and quality of their muscle. We discovered that patients with more muscle, especially higher-quality muscle, had a significantly lower risk of death and were less likely to develop end-stage kidney disease. Conversely, lower-quality muscle was associated with an increased risk of death. These findings suggest that maintaining good muscle mass may improve outcomes for patients with ADPKD. These data can inform future strategies for improving outcomes in people with ADPKD.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Im DW, Jung J, Ha M, et al. Associations of Skeletal Muscle Mass and Body Mass Index With Clinical Outcomes in Autosomal-Dominant Polycystic Kidney Disease: An Observational Study. Am J Kidney Dis. 2025. PMID: 41101718. doi:10.1053/j.ajkd.2025.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。